225 related articles for article (PubMed ID: 34932882)
1. SGLT inhibitors on weight and body mass: A meta-analysis of 116 randomized-controlled trials.
Cheong AJY; Teo YN; Teo YH; Syn NL; Ong HT; Ting AZH; Chia AZQ; Chong EY; Chan MY; Lee CH; Lim AYL; Kong WKF; Wong RCC; Chai P; Sia CH
Obesity (Silver Spring); 2022 Jan; 30(1):117-128. PubMed ID: 34932882
[TBL] [Abstract][Full Text] [Related]
2. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials.
Teo YN; Ting AZH; Teo YH; Chong EY; Tan JTA; Syn NL; Chia AZQ; Ong HT; Cheong AJY; Li TY; Poh KK; Yeo TC; Chan MY; Wong RCC; Chai P; Sia CH
Am J Cardiovasc Drugs; 2022 May; 22(3):299-323. PubMed ID: 35316484
[TBL] [Abstract][Full Text] [Related]
3. The impact of sodium-glucose cotransporter inhibitors on blood pressure: a meta-analysis and metaregression of 111 randomized-controlled trials.
Teo YH; Chia AZQ; Teo YN; Chong EY; Syn NL; Cheong JYA; Ong HT; Wee CF; Ting AZH; Tan JTA; Li TYW; Kong WKF; Lee CH; Chan MY; Wong RCC; Yeo TC; Chai P; Sia CH
J Hypertens; 2022 Dec; 40(12):2353-2372. PubMed ID: 36018229
[TBL] [Abstract][Full Text] [Related]
4. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.
Teo YH; Teo YN; Syn NL; Kow CS; Yoong CSY; Tan BYQ; Yeo TC; Lee CH; Lin W; Sia CH
J Am Heart Assoc; 2021 Feb; 10(5):e019463. PubMed ID: 33625242
[TBL] [Abstract][Full Text] [Related]
5. Effects of Sodium-glucose Cotransporter 2 Inhibitor Monotherapy on Weight Changes in Patients With Type 2 Diabetes Mellitus: a Bayesian Network Meta-analysis.
Wang H; Yang J; Chen X; Qiu F; Li J
Clin Ther; 2019 Feb; 41(2):322-334.e11. PubMed ID: 30711143
[TBL] [Abstract][Full Text] [Related]
6. Effects of sodium-glucose cotransporter (SGLT) inhibitors in addition to insulin therapy on glucose control and safety outcomes in adults with type 1 diabetes: A meta-analysis of randomized controlled trials.
Lu J; Tang L; Meng H; Zhao J; Liang Y
Diabetes Metab Res Rev; 2019 Oct; 35(7):e3169. PubMed ID: 30974510
[TBL] [Abstract][Full Text] [Related]
7. Metabolic effects of the dual SGLT 1/2 inhibitor sotagliflozin on blood pressure and body weight reduction in people with diabetes: An updated meta-analysis of randomized controlled trials.
Wu J; Zhao X; Chen H; Zhu S
J Diabetes Complications; 2022 Dec; 36(12):108352. PubMed ID: 36370667
[TBL] [Abstract][Full Text] [Related]
8. Sodium-glucose cotransporter inhibitors as add-on therapy in addition to insulin for type 1 diabetes mellitus: A meta-analysis of randomized controlled trials.
Zou H; Liu L; Guo J; Wang H; Liu S; Xing Y; Deng C; Xiao Y; Zhou Z
J Diabetes Investig; 2021 Apr; 12(4):546-556. PubMed ID: 33245620
[TBL] [Abstract][Full Text] [Related]
9. Relationship Between SGLT-2i and Ocular Diseases in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials.
Zhou B; Shi Y; Fu R; Ni H; Gu L; Si Y; Zhang M; Jiang K; Shen J; Li X; Sun X
Front Endocrinol (Lausanne); 2022; 13():907340. PubMed ID: 35692406
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
Scheen AJ
Circ Res; 2018 May; 122(10):1439-1459. PubMed ID: 29748368
[TBL] [Abstract][Full Text] [Related]
11. Dose-ranging effects of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis.
Pinto LC; Rados DV; Remonti LR; Viana MV; Leitão CB; Gross JL
Arch Endocrinol Metab; 2022 Mar; 66(1):68-76. PubMed ID: 35263050
[TBL] [Abstract][Full Text] [Related]
12. Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials.
Tang HL; Li DD; Zhang JJ; Hsu YH; Wang TS; Zhai SD; Song YQ
Diabetes Obes Metab; 2016 Dec; 18(12):1199-1206. PubMed ID: 27407013
[TBL] [Abstract][Full Text] [Related]
13. Comparing and Contrasting the Effects of the SGLT Inhibitors Canagliflozin and Empagliflozin on the Progression of Retinopathy.
Herat LY; Matthews JR; Rakoczy EP; Schlaich MP; Matthews VB
Front Biosci (Landmark Ed); 2023 Apr; 28(4):83. PubMed ID: 37114550
[TBL] [Abstract][Full Text] [Related]
14. High-dose sodium-glucose co-transporter-2 inhibitors are superior in type 2 diabetes: A meta-analysis of randomized clinical trials.
Shi FH; Li H; Shen L; Fu JJ; Ma J; Gu ZC; Lin HW
Diabetes Obes Metab; 2021 Sep; 23(9):2125-2136. PubMed ID: 34048142
[TBL] [Abstract][Full Text] [Related]
15. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
Handelsman Y
Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707
[TBL] [Abstract][Full Text] [Related]
16. The effects of sodium glucose co-transporter (SGLT) 2 inhibitors on hematocrit levels: a systematic review and meta-analysis of randomized controlled trials.
Wang X; Fu R; Liu H; Ma Y; Qiu X; Dong Z
Ann Palliat Med; 2021 Jun; 10(6):6467-6481. PubMed ID: 34118855
[TBL] [Abstract][Full Text] [Related]
17. Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With Type 1 Diabetes: A Network Meta-Analysis.
Kim YJ; Hwang SD; Lim S
Front Endocrinol (Lausanne); 2020; 11():553. PubMed ID: 32973680
[TBL] [Abstract][Full Text] [Related]
18. The effect of sodium-glucose co-transporter-2 (SGLT2) inhibitors on blood interleukin-6 concentration: a systematic review and meta-analysis of randomized controlled trials.
Gohari S; Ismail-Beigi F; Mahjani M; Ghobadi S; Jafari A; Ahangar H; Gohari S
BMC Endocr Disord; 2023 Nov; 23(1):257. PubMed ID: 37996879
[TBL] [Abstract][Full Text] [Related]
19. Effects of Sodium/Glucose Cotransporter Inhibitors on Atrial Fibrillation and Stroke: A Meta-Analysis.
Ong HT; Teo YH; Teo YN; Syn NL; Wee CF; Leong S; Yip ASY; See RM; Ting AZH; Chia AZ; Cheong AJY; Tan BY; Ho JS; Yeo LL; Leow AS; Yeo TC; Wong RC; Chai P; Kojodjojo P; Sia CH
J Stroke Cerebrovasc Dis; 2022 Jan; 31(1):106159. PubMed ID: 34689051
[TBL] [Abstract][Full Text] [Related]
20. Dose-dependent renoprotection efficacy of sglt2 inhibitors in type 2 diabetes: systematic review and network meta-analysis.
Hegde NC; Kumar A; Patil AN; Bhattacharjee S; Gamad N; Kasudhan KS; Kumar V; Rastogi A
Acta Diabetol; 2023 Oct; 60(10):1311-1331. PubMed ID: 37322184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]